Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:diabetes
|
| gptkbp:brand |
gptkb:Humulin
|
| gptkbp:clinical_trial |
Phase IV
Phase III insulin therapy studies |
| gptkbp:clinical_use |
insulin regimen
mealtime insulin basal-bolus therapy |
| gptkbp:contraindication |
severe hypoglycemia
hypersensitivity to insulin |
| gptkbp:dosage_form |
U-100
U-500 |
| gptkbp:duration |
5 to 8 hours
|
| gptkbp:effective_date |
gptkb:1982
|
| gptkbp:form |
injection
vials pre-filled pens |
| gptkbp:highest_point |
2 to 3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Humulin R
|
| gptkbp:indication |
type 2 diabetes
type 1 diabetes |
| gptkbp:ingredients |
insulin human
|
| gptkbp:interacts_with |
gptkb:beer
beta-blockers thiazide diuretics oral hypoglycemics |
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States |
| gptkbp:mechanism_of_action |
lowers blood glucose levels
|
| gptkbp:packaging |
pens
single-dose vials multi-dose vials |
| gptkbp:patient_education |
proper injection technique
carry glucose source recognize hypoglycemia symptoms diet and exercise importance monitor blood glucose |
| gptkbp:premiered_on |
30 minutes
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:research_areas |
diabetes treatment
insulin delivery systems glycemic control |
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:side_effect |
weight gain
injection site reactions hypoglycemia |
| gptkbp:storage |
refrigerated
|
| gptkbp:type |
short-acting insulin
|
| gptkbp:used_for |
diabetes management
|
| gptkbp:bfsParent |
gptkb:Humulin
|
| gptkbp:bfsLayer |
5
|